The power of negative thinking: Which cells limit tumor immunity?

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5157-5159

  Tang, Siuwah ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; BLOOD DONOR; BONE MARROW CELL; CANCER STAGING; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; MELANOMA; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; NOTE; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; FEMALE; HUMANS; MALE; MELANOMA; MYELOID CELLS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84866914804     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2418     Document Type: Note

References (12)

1. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T cell proliferation in patients with melanoma. Clin Cancer Res 2012;18:5215-23.
2. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011;11:802-7.
3. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2011;61:255-63.
4. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-53. (Pubitemid 47041228)
5. Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008;26:3235-41.
6. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2008;66:9299-307. (Pubitemid 44521152)
7. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
8. Unlu S, Tang S, Wang EN, Martinez I, Tang D, Bianchi ME, et al. Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. PLoS One 2012;7:e38899.
9. Yu Y, Cao L, Yang L, Kang R, Lotze M, Tang D. microRNA 30A promotes autophagy in response to cancer therapy. Autophagy 2012;8:853-5.
10. Lotze MT, Buchser W, Liang X. Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy 2012 Aug 1 [Epub ahead of print].
11. Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM, et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci 2012;109:7031-6.
12. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012;13:832-42.